Allergy/Imm Medical News about Multiple Sclerosis; Interferon-beta Therapy

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Novel therapies for children with severe asthma

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Improving Compliance with Interferon-beta Therapy in Patients with Multiple Sclerosis
CNS Drugs, 06/03/09

Portaccio E et al. - Individualized patient education and support are critical to improve adherence to therapy in the long term. Approaches aimed at reducing the proportion of subjects interrupting IFNbeta encompass both pharmacological and non-pharmacological interventions, and may involve several professional figures, such as the neurologist, the psychologist, the pharmacist, the physical and speech therapist, and the nurse. Recently, the development of new IFNbeta formulations, with reduced immunogenic potential, has offered an additional approach to improving patient adherence. Biferonex(R) is a pH neutral and human serum albumin-free IFNbeta-1a. A phase III, 2-year study of the product involving patients with RRMS has been conducted, but the results were not considered conclusive enough to allow approval in Europe. Rebif(R) New Formulation (RNF) is a formulation of INF[beta]-1a that is not produced using fetal bovine serum and that does not have human serum albumin as an excipient. The formulation has been approved in Europe and an application for approval has been filed in the US.

<< Previous
Genetic Engineering of Allergens for Immunotherapy

Next >>
Parent-reported adverse food reactions in Hong Kong Chinese...